Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib

Palbociclib is a first-in-class potent oral inhibitor of cyclin-dependent kinase (CDK)4/6 that was approved in the USA in 2015 and in Japan in 2017. Next-generation abemaciclib was approved in the USA and Japan in 2018. The use of palbociclib results in a high frequency of bone marrow suppression, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kikuchi, Mariko, Tanaka, Yoko, Yokota, Mitsuo, Nishimiya, Hiroshi, Katoh, Hiroshi, Sengoku, Norihiko, Kosaka, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873425/
https://www.ncbi.nlm.nih.gov/pubmed/31798870
http://dx.doi.org/10.3892/br.2019.1248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873425/
https://www.ncbi.nlm.nih.gov/pubmed/31798870
http://dx.doi.org/10.3892/br.2019.1248

Ejemplares similares